A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs LY 2780301 (Primary) ; Gemcitabine
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INPAKT
  • Most Recent Events

    • 24 Jul 2017 Results published in the European Journal of Cancer
    • 11 Jul 2016 Status changed from recruiting to completed.
    • 21 Jan 2014 Planned number of patients changed from 44 to 50 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top